Arix Bioscience logo

ARIX - Arix Bioscience Share Price

196p -0.5  -0.3%

Last Trade - 20/01/21

Small Cap
Market Cap £266.5m
Enterprise Value £223.1m
Revenue £432k
Position in Universe 744th / 1804
Unlock ARIX Revenue
Relative Strength (%)
1m -8.98%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -16.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.001 0.64 1.86 1.33 0.51 0.75 1.00 +374.3%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, ArixBioscience PLC revenues decreased 28% to £192K. Net incometotaled £49M vs. loss of £38.9M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Net Income reflectsChange in fair value of investments increase from £39.1M(expense) to £42.6M (income), Foreign exchange gainsincrease from £743K to £9.3M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ARIX
Graphical History


ARIX Revenue Unlock ARIX Revenue

Net Income

ARIX Net Income Unlock ARIX Revenue

Normalised EPS

ARIX Normalised EPS Unlock ARIX Revenue

PE Ratio Range

ARIX PE Ratio Range Unlock ARIX Revenue

Dividend Yield Range

ARIX Dividend Yield Range Unlock ARIX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARIX EPS Forecasts Unlock ARIX Revenue
Profile Summary

Arix Bioscience plc is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. Its principal activity is to source, finance and develop healthcare and life science businesses across the world. The Company focuses on acquiring interests in, and provide operational oversight to, healthcare and life science businesses with which it partners in the healthcare and life science sector. The Company holds interests in BioMotiv, OptiKira LLC, Autolus, Depixus SAS, Verona Pharma plc and Artios Pharma Ltd. The Company has agreements with universities in the United Kingdom, Europe and Australia, providing direct access to new technologies. It also has access to a range of research projects from the United States academic institutions. Its subsidiaries include Arix Bioscience Holdings Limited, Arix US Inc and Arthurian Life Sciences GP Limited.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 15, 2015
Public Since February 17, 2017
No. of Shareholders: n/a
No. of Employees: 730
Sector Financials
Industry Holding Companies
Exchange London Stock Exchange (Full)
Shares in Issue 135,609,653
Free Float (0.0%)
Eligible for
ARIX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ARIX
Upcoming Events for ARIX
Frequently Asked Questions for Arix Bioscience
What is the Arix Bioscience share price?

As of 20/01/21, shares in Arix Bioscience are trading at 196p, giving the company a market capitalisation of £266.5m. This share price information is delayed by 15 minutes.

How has the Arix Bioscience share price performed this year?

Shares in Arix Bioscience are currently trading at 196p and the price has moved by 0.105k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arix Bioscience price has moved by 0.128k% over the past year.

What are the analyst and broker recommendations for Arix Bioscience?

Of the analysts with advisory recommendations for Arix Bioscience, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arix Bioscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Arix Bioscience next release its financial results?

Arix Bioscience is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Arix Bioscience dividend yield?

Arix Bioscience does not currently pay a dividend.

Does Arix Bioscience pay a dividend?

Arix Bioscience does not currently pay a dividend.

When does Arix Bioscience next pay dividends?

Arix Bioscience does not currently pay a dividend.

How do I buy Arix Bioscience shares?

To buy shares in Arix Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Arix Bioscience?

Shares in Arix Bioscience are currently trading at 196p, giving the company a market capitalisation of £266.5m.

Where are Arix Bioscience shares listed? Where are Arix Bioscience shares listed?

Here are the trading details for Arix Bioscience:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: ARIX
What kind of share is Arix Bioscience?

Based on an overall assessment of its quality, value and momentum, Arix Bioscience is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Arix Bioscience share price forecast 2021?

Shares in Arix Bioscience are currently priced at 196p. At that level they are trading at 18.92% discount to the analyst consensus target price of 241.74.

Analysts covering Arix Bioscience currently have a consensus Earnings Per Share (EPS) forecast of -0.02265 for the next financial year.

How can I tell whether the Arix Bioscience share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arix Bioscience. Over the past six months, the relative strength of its shares against the market has been 0.103k%. At the current price of 196p, shares in Arix Bioscience are trading at 73.14% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Arix Bioscience PE Ratio?

The Arix Bioscience PE ratio based on its reported earnings over the past 12 months is 17.43. The shares are currently trading at 196p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Arix Bioscience?

Arix Bioscience's management team is headed by:

Trevor Jones - NID
Giles Kerr - NID
Arthur Pappas - NID
Mark Breuer - NID
Marcus Karia - FID
Naseem Amin - CHM
Jonathan Tobin - MDR
Mark Chin - OTH
Christian Schetter - OTH
Edward Rayner - OTH
John Cassidy - OTH
Robert Lyne - COO
Roberto Lacone - OTH
Tim Xu - OTH
Who are the major shareholders of Arix Bioscience?

Here are the top five shareholders of Arix Bioscience based on the size of their shareholding:

Acacia Research Corp Investment Advisor
Percentage owned: 19.05% (25.8m shares)
Fosun International Holdings, Ltd. Corporation
Percentage owned: 8.19% (11.1m shares)
Ruffer LLP Investment Advisor/Hedge Fund
Percentage owned: 6.03% (8.18m shares)
Takeda Ventures, Inc. Venture Capital
Percentage owned: 5.53% (7.50m shares)
Chipperton (Christopher) Individual Investor
Percentage owned: 5.12% (6.94m shares)
Similar to ARIX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.